Pneumococcal capsular polysaccharide serotype 6A (PPS 6A)

Pneumococcal capsular polysaccharide serotype 6A is a complex carbohydrate polymer that forms the outermost protective layer of Streptococcus pneumoniae serotype 6A [2, 9]. It serves as a critical virulence factor by shielding the bacterium from the host's immune system, specifically by inhibiting opsonophagocytosis by neutrophils and macrophages [2, 16, 18]. This evasion mechanism allows the pathogen to colonize the nasopharynx and potentially progress to invasive diseases such as pneumonia, meningitis, and bacteremia [9, 12, 16]. Serotype 6A is a major cause of morbidity and mortality, particularly in children and the elderly [15, 16]. In the context of therapeutics, this polysaccharide is a primary target for pneumococcal conjugate vaccines (PCVs) [1, 6, 11]. Modern vaccines like PCV13, PCV15, PCV20, and PCV21 include purified serotype 6A polysaccharide conjugated to a carrier protein, such as CRM197, to enhance immunogenicity and induce long-term B-cell memory [1, 3, 21, 24]. These vaccines work by stimulating the production of specific antibodies that bind to the capsule, thereby facilitating bacterial clearance through the complement system and phagocytic cells [6, 11, 15]. A significant challenge associated with targeting this molecule is serotype replacement, where the reduction of vaccine-covered serotypes in a population leads to the emergence of non-vaccine serotypes [2, 5, 13].

Other names

Streptococcus pneumoniae capsular polysaccharide serotype 6ACPS 6APneumococcal polysaccharide type 6AUS Type 6

Stimulation of active immunity through the production of serotype-specific antibodies that opsonize the bacterium for phagocytic clearance [1, 6, 11].